Komori
Obara Group (6877) · FactFirst-half R&D expenditure increased

Research and Development Investment

First written in FY2016-Q3. 15 of 31 entries say "Restated". Latest entry: FY2026-H1.

31entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q3 – FY2026-H12016: 220162017: 320172018: 420182019: 420192020: 420202021: 220212022: 420222023: 420232024: 220242025: 120252026: 1
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 191 companies write about · 0 as a headwind · 180 as a tailwind

45 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1First-half R&D expenditure increasedAnnual report

    「Total R&D expenditure for the cumulative interim period of the consolidated fiscal year was ¥264 million. There were no material changes in the status of the Group’s R&D activities during the cumulative interim period of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure increased from ¥217 million in the same period of the previous year to ¥264 million.
  2. FY2025-H1Decline in first-half research and development expensesAnnual report

    「Total R&D expenditure for the cumulative interim period of the consolidated fiscal year was ¥217 million. There were no material changes in the status of the Group’s R&D activities during the cumulative interim period of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥247 million in the same period of the previous year to ¥217 million.
  3. FY2024-Q2Decline in first-half research and development expensesAnnual report

    「Total R&D expenditure for the cumulative second quarter of the consolidated fiscal year was ¥247 million.」

    First-half R&D expenditure was ¥247 million, down from ¥379 million in the same period of the previous year. The company stated that there were no material changes in the status of R&D activities.
  4. FY2024-Q1Quarterly R&D expenses decreasedAnnual report

    「Total R&D expenditure for the cumulative first quarter of the consolidated fiscal year was ¥117 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥165 million in the same period of the previous year to ¥117 million.
  5. FY2023Decline in R&D ExpensesAnnual report

    「R&D expenditure for the consolidated fiscal year was ¥630 million,」

    R&D activities and specific product development continued, while R&D expenditure declined from ¥691 million in the previous consolidated fiscal year to ¥630 million.
  6. FY2023-Q3Quarterly R&D expenses decreasedAnnual report

    「Total R&D expenditure for the cumulative third quarter of the consolidated fiscal year was ¥498 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥527 million in the same period of the previous year to ¥498 million.
  7. FY2023-Q2First-half R&D expenditure increasedAnnual report

    「Total R&D expenditure for the cumulative second quarter of the consolidated fiscal year was ¥379 million.」

    First-half R&D expenditure was ¥379 million, up from ¥333 million in the same period of the previous year. The company stated that there were no material changes in the status of R&D activities.
  8. FY2023-Q1Quarterly R&D expenses decreasedAnnual report

    「Total research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥165 million.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥171 million in the same period of the previous year to ¥165 million.
  9. FY2022Decline in R&D ExpensesAnnual report

    「R&D expenditure for the consolidated fiscal year was ¥691 million,」

    R&D activities continued and specific product results were also disclosed, while R&D expenditure declined from ¥818 million in the previous consolidated fiscal year to ¥691 million.
  10. FY2022-Q3Quarterly R&D expenses decreasedAnnual report

    「Total R&D expenditure for the cumulative third quarter of the consolidated fiscal year was ¥527 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥621 million in the same period of the previous year to ¥527 million.
  11. FY2022-Q2First-half R&D expenditure increasedAnnual report

    「Total R&D expenditure for the cumulative second quarter of the consolidated fiscal year was ¥333 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, first-half R&D expenditure increased from ¥313 million in the same period of the previous year to ¥333 million.
  12. FY2022-Q1Quarterly R&D expenses decreasedAnnual report

    「Total R&D expenditure for the cumulative first quarter of the consolidated fiscal year was ¥171 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥221 million in the same period of the previous year to ¥171 million.
  13. FY2021-Q2Decline in first-half research and development expensesAnnual report

    「Total R&D expenditure for the cumulative second quarter of the consolidated fiscal year was ¥313 million. There were no material changes in the status of the Group’s R&D activities during the cumulative second quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥480 million in the same period of the previous year to ¥313 million.
  14. FY2021-Q1Quarterly R&D expenses decreasedAnnual report

    「Total R&D expenditure for the cumulative first quarter of the consolidated fiscal year was ¥148 million. There were no material changes in the status of the Group’s R&D activities during the cumulative first quarter of the consolidated fiscal year.」

    While stating that there were no material changes in the status of R&D activities, R&D expenditure declined from ¥221 million in the same period of the previous year to ¥148 million.
  15. FY2020Decline in R&D ExpensesAnnual report

    「R&D expenditure for the consolidated fiscal year was ¥818 million,」

    R&D activities continued, while R&D expenditure declined from ¥992 million in the previous fiscal year to ¥818 million.
  16. FY2020-Q3RestatedAnnual report

    「Total R&D expenditure for the cumulative third quarter of the consolidated fiscal year was ¥621 million. There were no material changes in the status of the Group’s R&D activities during the cumulative third quarter of the consolidated fiscal year.」

    The cumulative R&D expenditure for the quarter was disclosed as ¥621 million, with no material changes in the status of R&D activities.
  17. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the six-month period of the current consolidated fiscal year were ¥480 million. The company also states that there were no material changes in the status of its group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The cumulative R&D expenditure for the quarter was disclosed as ¥480 million, with no material changes in R&D activities.
  18. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the three-month period of the current consolidated fiscal year were ¥221 million. The company also states that there were no material changes in the status of its group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The company discloses ¥221 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  19. FY2019RestatedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥992 million,」

    The company discloses ¥992 million as its full-year research and development expenses and states that research and development activities are continuing in both the welding equipment and surface grinding equipment businesses.
  20. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the nine-month period of the current consolidated fiscal year were ¥747 million. The company also states that there were no material changes in the status of its group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The company discloses ¥747 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  21. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the six-month period of the current consolidated fiscal year were ¥481 million. The company also states that there were no material changes in the status of its group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The company discloses ¥481 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  22. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the three-month period of the current consolidated fiscal year were ¥229 million. The company also states that there were no material changes in the status of its group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The company discloses ¥229 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  23. FY2018RestatedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥1,086 million,」

    The company discloses ¥1,086 million as its full-year research and development expenses.
  24. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the nine-month period of the current consolidated fiscal year were ¥862 million. The company also states that there were no material changes in the status of its group's research and development activities during the nine-month period of the current consolidated fiscal year.」

    The company discloses ¥862 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  25. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the six-month period of the current consolidated fiscal year were ¥589 million. The company also states that there were no material changes in the status of its group's research and development activities during the six-month period of the current consolidated fiscal year.」

    The company discloses ¥589 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  26. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the three-month period of the current consolidated fiscal year were ¥301 million. The company also states that there were no material changes in the status of its group's research and development activities during the three-month period of the current consolidated fiscal year.」

    The company discloses ¥301 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  27. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the nine-month period of the current consolidated fiscal year were ¥750 million.」

    The company discloses ¥750 million as year-to-date research and development expenses for the current quarter and states that there were no material changes in its research and development activities.
  28. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the six-month period of the current consolidated fiscal year were ¥490 million.」

    The company discloses ¥490 million as year-to-date research and development expenses for the current quarter.
  29. FY2017-Q1RestatedAnnual report

    「Total research and development expenses for the three-month period of the current consolidated fiscal year were ¥259 million.」

    The company discloses ¥259 million as year-to-date research and development expenses for the current quarter.
  30. FY2016RestatedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥1,043 million,」

    The company discloses ¥1,043 million as its full-year research and development investment.
  31. FY2016-Q3First statedAnnual report

    「Total research and development expenses for the nine-month period of the current consolidated fiscal year were ¥769 million.」

    The company discloses research and development expenses for the year-to-date period of the current quarter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Obara Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.